The Journal of dermatological treatment · 2025
Comparative efficacy and safety of targeted narrowband ultraviolet B, 308-nm excimer laser, and 308-nm excimer lamp in vitiligo: a retrospective study.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tantivithiwate Thamonwan, Chaiyabutr Chayada, Wongpraparut Chanisada, Yothachai Punyanut, Nuntawisuttiwong Nuttaporn, Silpa-Archa Narumol
Аннотация
BACKGROUND: Data directly comparing targeted narrowband ultraviolet B (NB-UVB), 308-nm excimer laser, and 308-nm excimer lamp for vitiligo are limited.
OBJECTIVES: We compared the efficacy and safety of these three modalities in vitiligo.
METHODS: In this retrospective study, we reviewed the medical records of vitiligo patients at the Photodermatology Clinic, Siriraj Hospital. Patients received either targeted NB-UVB (group A), a 308-nm excimer laser (group B), or a 308-nm excimer lamp (group C), administered two to three times per week for at least 3 months. Photographs taken before and after therapy were evaluated. The primary outcome was repigmentation, graded on a five-tier scale: poor (0-25%), fair (26-50%), good (51-75%), very good (76-90%), and excellent (91-100%). The secondary outcome was treatment-related adverse events.
RESULTS: No statistically significant differences in efficacy were observed among the three groups, indicated by a very good to excellent response in 42.4% (group A), 17.6% (group B), and 29.4% (group C). Although group A showed higher response rates at 3 and 6 months, differences were not significant. Adverse effects were significantly more frequent in group C.
CONCLUSIONS: All three devices demonstrated comparable efficacy and promoted rapid repigmentation. However, the excimer lamp had the highest rate of adverse effects.
OBJECTIVES: We compared the efficacy and safety of these three modalities in vitiligo.
METHODS: In this retrospective study, we reviewed the medical records of vitiligo patients at the Photodermatology Clinic, Siriraj Hospital. Patients received either targeted NB-UVB (group A), a 308-nm excimer laser (group B), or a 308-nm excimer lamp (group C), administered two to three times per week for at least 3 months. Photographs taken before and after therapy were evaluated. The primary outcome was repigmentation, graded on a five-tier scale: poor (0-25%), fair (26-50%), good (51-75%), very good (76-90%), and excellent (91-100%). The secondary outcome was treatment-related adverse events.
RESULTS: No statistically significant differences in efficacy were observed among the three groups, indicated by a very good to excellent response in 42.4% (group A), 17.6% (group B), and 29.4% (group C). Although group A showed higher response rates at 3 and 6 months, differences were not significant. Adverse effects were significantly more frequent in group C.
CONCLUSIONS: All three devices demonstrated comparable efficacy and promoted rapid repigmentation. However, the excimer lamp had the highest rate of adverse effects.